FTY720 in Patients With Primary Progressive Multiple Sclerosis (INFORMS)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00731692
First received: August 7, 2008
Last updated: May 21, 2014
Last verified: May 2014
  Purpose

The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS.


Condition Intervention Phase
Primary Progressive Multiple Sclerosis
Drug: FTY720
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • To evaluate the effect of FTY720 relative to placebo on delaying the time to sustained disability progression for patients treated for at least 36 months [ Time Frame: When the last still ongoing patient in the double-blind treatment phase completes Month 36 of the study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the safety and tolerability of FTY720 compared to placebo in patients with PPMS [ Time Frame: when the last patient still ongoing in the study completes Month 36 of the double blind treatment phase ] [ Designated as safety issue: Yes ]
  • To evaluate the effect of FTY720 relative to placebo on conventional MRI parameters [ Time Frame: When the last still ongoing patient in the double-blind treatment phase completes Month 36 of the study ] [ Designated as safety issue: No ]
  • To evaluate the effect of FTY720 relative to placebo on Patient Reported Outcomes [ Time Frame: When the last still ongoing patient in the double-blind treatment phase completes Month 36 of the study ] [ Designated as safety issue: No ]

Enrollment: 969
Study Start Date: July 2008
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FTY720D 0.5 mg Drug: FTY720
Placebo Comparator: Placebo Drug: Placebo
Capsules

  Eligibility

Ages Eligible for Study:   25 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

General

  1. sign written informed consent prior to participating in the study
  2. 25 through 65 years of age inclusive
  3. females of childbearing potential must:

    • have a negative pregnancy test at Baseline (prior to randomization) and
    • use simultaneously two forms of effective contraception during the treatment and 3-months after discontinuation of study medication

Primary Progressive Multiple sclerosis.

  1. diagnosis of primary progressive multiple sclerosis (according to the 2005 Revised McDonald criteria):
  2. time since first reported symptoms between 2 and 10 years
  3. evidence of clinical disability progression in the 2 years prior to Screening
  4. disability status at Screening

    • EDSS score of 3.5-6.0 inclusive
    • pyramidal functional system score of 2 or more
    • 25'TWT less than 30 seconds

Exclusion Criteria:

PPMS specific:

  • History of relapses/attacks
  • Progressive neurological disorder other than PPMS
  • Pure cerebellar syndrome or pure visual progressive syndrome or pure
  • cognitive progressive syndrome
  • Presence of spinal cord compression at screening MRI
  • Relevant history of vitamin B12 deficit
  • Evidence of syphilis or borreliosis at Screening

Cardiovascular conditions:

  • Myocardial infarction within the past 6 months or current unstable ischemic heart disease
  • History of angina pectoris due to coronary spasm or history of Raynaud's phenomenon
  • Severe cardiac failure or cardiac arrest
  • History of symptomatic bradycardia
  • Resting pulse <55 bpm pre-dose
  • History of sick sinus syndrome or sino-atrial heart block
  • History or presence of second and third degree AV block or an increase QT interval (QTc>440 ms)
  • Arrythmia requiring treatment with class III antiarrythmic drugs
  • History of positive tilt test from workout of vasovagal syncope
  • Hypertension, not controlled with medication

Pulmonary:

  • Severe respiratory disease or pulmonary fibrosis
  • TB
  • Abnormal X-ray, suggestive of active pulmonary disease
  • Abnormal PFT: <70% of predicted for FEV1 and FVC; <60% for DLCO
  • Patients receiving chronic (daily) therapies for asthma

Hepatic:

  • Known history of alcohol abuse, chronic liver or biliary disease
  • Total or conjugated Brb >ULN, unless in context of Gilbert's syndrome
  • AP >1.5xULN; ALT/AST >2xULN; GGT>3xULN

Other:

  • History of chronic disease of the immune system other than MS
  • Malignancy (other than successfully treated SCC or BCC)
  • Diabetes Mellitus
  • Macular Edema present at screening
  • HIV, Hepatitis C or B, other active infection
  • History of total lymphoid irradiation or bone marrow transplantation
  • Serum creatinine >1.7 mg/dl
  • WBC <3500 cells/mm3
  • Lymphocyte count <800 cells/mm3
  • History of substance abuse or any other factor that may interfere with subject ability to cooperate and comply with the study procedures
  • Unable to undergo MRI scans
  • Participation in any therapeutical clinical research study in the 6 months prior to randomization
  • Pregnant or lactating women
  • Drugs requiring wash-out period:

    3 months:

    • Systemic corticosteroids or ACTH
    • INF-beta

      6 months:

    • Immunosuppressive medication
    • Immunoglobulins
    • Monoclonal antibodies
  • Drugs that exclude participation in the study:
  • Cladribine
  • Cyclophosphamide
  • Mitoxantrone (except: patients who received a cumulative dose of no more than 60mg/m2 more than 5 years ago could enter the study)

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00731692

  Hide Study Locations
Locations
United States, California
Novartis Investigative Site
Newport Beach, California, United States, 92660
Novartis Investigative Site
Sacramento, California, United States, 95817
United States, Colorado
Novartis Investigative Site
Aurora, Colorado, United States, 80045
United States, Florida
Novartis Investigative Site
Pompano Beach, Florida, United States, 33060
Novartis Investigative Site
Tampa, Florida, United States, 33609
United States, Georgia
Novartis Investigative Site
Atlanta, Georgia, United States, 30302
United States, Illinois
Novartis Investigative Site
Chicago, Illinois, United States, 60611
Novartis Investigative Site
Chicago, Illinois, United States, 60637
United States, Kansas
Novartis Investigative Site
Kansas City, Kansas, United States, 66160
United States, Maryland
Novartis Investigative Site
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Novartis Investigative Site
Boston, Massachusetts, United States, 02135
Novartis Investigative Site
Brookline, Massachusetts, United States, 02445
United States, Michigan
Novartis Investigative Site
Detroit, Michigan, United States, 48201
United States, Missouri
Novartis Investigative Site
St. Louis, Missouri, United States, 63110
United States, New Jersey
Novartis Investigative Site
Teaneck, New Jersey, United States, 07666
United States, New York
Novartis Investigative Site
Buffalo, New York, United States, 14203
Novartis Investigative Site
New York, New York, United States, 10029
Novartis Investigative Site
Rochester, New York, United States, 14642
Novartis Investigative Site
Stony Brook, New York, United States, 11794
United States, North Carolina
Novartis Investigative Site
Charlotte, North Carolina, United States, 28207
Novartis Investigative Site
Durham, North Carolina, United States, 27705
United States, Ohio
Novartis Investigative Site
Cleveland, Ohio, United States, 44195
Novartis Investigative Site
Columbus, Ohio, United States, 43221
United States, Pennsylvania
Novartis Investigative Site
Pittsburgh, Pennsylvania, United States, 15213
United States, Tennessee
Novartis Investigative Site
Knoxville, Tennessee, United States, 37934
Novartis Investigative Site
Nashville, Tennessee, United States, 37212
United States, Texas
Novartis Investigative Site
Dallas, Texas, United States, 75390-9034
Novartis Investigative Site
Houston, Texas, United States, 77030
Novartis Investigative Site
San Antonio, Texas, United States, 78229
United States, Vermont
Novartis Investigative Site
Burlington, Vermont, United States, 05401
United States, Virginia
Novartis Investigative Site
Charlottesville, Virginia, United States, 22904
United States, Washington
Novartis Investigative Site
Seattle, Washington, United States, 98122
United States, Wisconsin
Novartis Investigative Site
Madison, Wisconsin, United States, 53792
Australia, New South Wales
Novartis Investigative Site
Camperdown, New South Wales, Australia, 2050
Novartis Investigative Site
Liverpool, New South Wales, Australia, 2170
Australia, Tasmania
Novartis Investigative Site
Hobart, Tasmania, Australia, 7000
Australia, Victoria
Novartis Investigative Site
Box Hill, Victoria, Australia, 3128
Novartis Investigative Site
Heidelberg, Victoria, Australia, 3084
Novartis Investigative Site
Parkville, Victoria, Australia, 3050
Belgium
Novartis Investigative Site
Charleroi, Belgium, 6000
Novartis Investigative Site
Edegem, Belgium, 2650
Novartis Investigative Site
Leuven, Belgium, 3000
Novartis Investigative Site
Liege, Belgium, 4000
Novartis Investigative Site
Melsbroek, Belgium, 1820
Novartis Investigative Site
Sint-Truiden, Belgium, 3800
Canada, Alberta
Novartis Investigative Site
Calgary, Alberta, Canada, T2N 2T9
Novartis Investigative Site
Edmonton, Alberta, Canada, T6G 2C8
Canada, British Columbia
Novartis Investigative Site
Burnaby, British Columbia, Canada, V5G 2X6
Novartis Investigative Site
Vancouver, British Columbia, Canada, V6T 2B5
Canada, Nova Scotia
Novartis Investigative Site
Halifax, Nova Scotia, Canada, B3H 4K4
Canada, Ontario
Novartis Investigative Site
Ottawa, Ontario, Canada, K1H 8L6
Novartis Investigative Site
Toronto, Ontario, Canada, M4N 3M5
Novartis Investigative Site
Toronto, Ontario, Canada, M5B 1W8
Canada, Quebec
Novartis Investigative Site
Gatineau, Quebec, Canada, J9J 0A5
Novartis Investigative Site
Greenfield Park, Quebec, Canada, J4V 2J2
Novartis Investigative Site
Montreal, Quebec, Canada, H2L 4M1
Novartis Investigative Site
Montreal, Quebec, Canada, H3A 2B4
Canada, Saskatchewan
Novartis Investigative Site
Regina, Saskatchewan, Canada, S4T 1A5
Czech Republic
Novartis Investigative Site
Olomouc, CZE, Czech Republic, 775 20
Novartis Investigative Site
Brno, Czech Republic, 656 91
Novartis Investigative Site
Ostrava-Poruba, Czech Republic, 708 00
Novartis Investigative Site
Plzen, Czech Republic, 301 00
Novartis Investigative Site
Praha 2, Czech Republic, 128 08
Novartis Investigative Site
Rychnov nad Kneznou, Czech Republic, 516 01
Novartis Investigative Site
Teplice, Czech Republic, 415 29
Denmark
Novartis Investigative Site
Aarhus, Denmark, 8000 C
Novartis Investigative Site
Sønderborg, Denmark, 6400
Finland
Novartis Investigative Site
Helsinki, Finland, 00100
Novartis Investigative Site
Tampere, Finland, 33100
Novartis Investigative Site
Turku, Finland, 20520
France
Novartis Investigative Site
Bordeaux Cedex, France, F-33076
Novartis Investigative Site
Lille Cedex, France, 59037
Novartis Investigative Site
Marseille cedex 05, France, 13385
Novartis Investigative Site
Montpellier, France, 34295
Novartis Investigative Site
Nantes Cedex 1, France, 44093
Novartis Investigative Site
Paris Cedex 13, France, 75651
Novartis Investigative Site
Rennes, France, F-35043
Novartis Investigative Site
Strasbourg, France, 67091
Germany
Novartis Investigative Site
Berlin, Germany, 10713
Novartis Investigative Site
Berlin, Germany, 13347
Novartis Investigative Site
Bochum, Germany, 44791
Novartis Investigative Site
Dresden, Germany, 01307
Novartis Investigative Site
Düsseldorf, Germany, 40225
Novartis Investigative Site
Erlangen, Germany, 91054
Novartis Investigative Site
Essen, Germany, 45147
Novartis Investigative Site
Freiburg, Germany, 79106
Novartis Investigative Site
Hannover, Germany, 30625
Novartis Investigative Site
Hennigsdorf, Germany, 16761
Novartis Investigative Site
Magdeburg, Germany, 39120
Novartis Investigative Site
Muenster, Germany, 48149
Novartis Investigative Site
München, Germany, 81675
Novartis Investigative Site
München, Germany, 81377
Novartis Investigative Site
Teupitz, Germany, 15755
Novartis Investigative Site
Trier, Germany, 54292
Novartis Investigative Site
Würzburg, Germany, 97080
Hungary
Novartis Investigative Site
Budapest, Hungary, 1145
Novartis Investigative Site
Budapest, Hungary, 1076
Novartis Investigative Site
Debrecen, Hungary, 4032
Novartis Investigative Site
Gyor, Hungary, 9024
Novartis Investigative Site
Miskolc, Hungary, 3526
Novartis Investigative Site
Veszprem, Hungary, H-8200
Italy
Novartis Investigative Site
Bari, BA, Italy, 70124
Novartis Investigative Site
Montichiari, BS, Italy, 25018
Novartis Investigative Site
Chieti, CH, Italy, 66100
Novartis Investigative Site
Catania, CT, Italy, 95123
Novartis Investigative Site
Genova, GE, Italy, 16132
Novartis Investigative Site
Milano, MI, Italy, 20122
Novartis Investigative Site
Milano, MI, Italy, 20132
Novartis Investigative Site
Cefalù, PA, Italy, 90015
Novartis Investigative Site
Padova, PD, Italy, 35128
Novartis Investigative Site
Roma, RM, Italy, 00189
Novartis Investigative Site
Roma, RM, Italy, 00133
Novartis Investigative Site
Orbassano, TO, Italy, 10043
Novartis Investigative Site
Gallarate, VA, Italy, 21013
Netherlands
Novartis Investigative Site
Amsterdam, Netherlands, 1105 AZ
Novartis Investigative Site
Breda, Netherlands, 4818 CK
Novartis Investigative Site
Eindhoven, Netherlands, 5623 EJ
Novartis Investigative Site
Nieuwegein, Netherlands, 3435 CM
Novartis Investigative Site
Nijmegen, Netherlands, 6525 GC
Novartis Investigative Site
Sittard-Geleen, Netherlands, 6162 BG
Poland
Novartis Investigative Site
Lodz, Poland, 90-153
Novartis Investigative Site
Lublin, Poland, 20-954
Novartis Investigative Site
Warszawa, Poland, 02-097
Novartis Investigative Site
Warszawa, Poland, 02-957
Spain
Novartis Investigative Site
Sevilla, Andalucia, Spain, 41009
Novartis Investigative Site
Badalona, Catalunya, Spain, 08916
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08036
Novartis Investigative Site
Girona, Cataluña, Spain, 17007
Novartis Investigative Site
L'Hospitalet de Llobregat, Cataluña, Spain, 08907
Novartis Investigative Site
Lleida, Cataluña, Spain, 25198
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46026
Novartis Investigative Site
Majadanonda, Madrid, Spain, 28220
Novartis Investigative Site
Bilbao, Pais Vasco, Spain, 48013
Novartis Investigative Site
Madrid, Spain, 28040
Novartis Investigative Site
Madrid, Spain
Sweden
Novartis Investigative Site
Göteborg, Sweden, 413 45
Novartis Investigative Site
Stockholm, Sweden, 17176
Switzerland
Novartis Investigative Site
Basel, Switzerland, 4031
Novartis Investigative Site
Bern, Switzerland, 3010
Novartis Investigative Site
Lausanne, Switzerland, 1011
Novartis Investigative Site
Lugano, Switzerland, 6900
Novartis Investigative Site
Zuerich, Switzerland, 8091
Turkey
Novartis Investigative Site
Ankara, Turkey, 06100
Novartis Investigative Site
Atakum / Samsun, Turkey, 55139
Novartis Investigative Site
Istanbul, Turkey, 34093
Novartis Investigative Site
Izmir, Turkey, 35340
Novartis Investigative Site
Yenisehir / Izmir, Turkey
United Kingdom
Novartis Investigative Site
Salford, Manchester, United Kingdom, M6 8HD
Novartis Investigative Site
Bristol, United Kingdom, BS16 1LE
Novartis Investigative Site
London, United Kingdom, NW1 2BU
Novartis Investigative Site
London, United Kingdom, W8 6RF
Novartis Investigative Site
London, United Kingdom, SE5 9RS
Novartis Investigative Site
London, United Kingdom, EC1A 7BE
Novartis Investigative Site
Newcastle Upon Tyne, United Kingdom, NE1 4LP
Novartis Investigative Site
Norwich, United Kingdom, NR4 7UY
Novartis Investigative Site
Sheffield, United Kingdom, S10 2JF
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided by Novartis

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT00731692     History of Changes
Other Study ID Numbers: CFTY720D2306, 2007-002627-32
Study First Received: August 7, 2008
Last Updated: May 21, 2014
Health Authority: United States: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration
Belgium: Federal Agency for Medicinal Products and Health Products
Canada: Health Canada
Czech Republic: State Institute for Drug Control
Denmark: Danish Medicines Agency
European Union: European Medicines Agency
Finland: Finnish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Italy: The Italian Medicines Agency
Netherlands: Medicines Evaluation Board (MEB)
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Spain: Spanish Agency of Medicines
Sweden: Medical Products Agency
Switzerland: Swissmedic
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Novartis:
FTY720, primary progressive multiple sclerosis,PPMS

Additional relevant MeSH terms:
Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Sclerosis
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Pathologic Processes
Fingolimod
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 21, 2014